Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad L Deal

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cleveland Clinic Journal of Medicine|January 28, 2003
Risedronate prevents hip fractures, but who should get therapy?Chad L Deal
Current Rheumatology Reports|April 18, 2007
Absolute fracture riskChad L Deal
Cleveland Clinic Journal of Medicine|February 5, 2013
Recent recommendations on steroid-induced osteoporosis: more targeted, but more complicatedChad L Deal
Women'S Health (London, England)|October 7, 2009
Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safetyChad L Deal, Michael W Draper
Arthritis and Rheumatism|October 3, 2006
Successes and failures in improving osteoporosis care after fragility fracture: results of a multiple-site clinical improvement projectJ Timothy Harrington, Chad L Deal
Arthritis Care & Research|July 19, 2012
Prevalence of oral glucocorticoid usage in the United States: a general population perspectiveRobert A Overman, Jun-Yen Yeh, Chad L Deal
Bone Reports|December 5, 2019
Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtendChad L Deal, Bruce H Mitlak, Yamei Wang, et al.
Arthritis Care & Research|April 11, 2014
United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosisRobert A Overman, Joshua C Toliver, Jun-Yen Yeh, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|February 22, 2015
DXA Utilization Between 2006 and 2012 in Commercially Insured Younger Postmenopausal WomenRobert A Overman, Joel F Farley, Jeffrey R Curtis, et al.
Arthritis and Rheumatism|March 1, 2007
The United States rheumatology workforce: supply and demand, 2005-2025Chad L Deal, Roderick Hooker, Timothy Harrington, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cleveland Clinic Journal of Medicine|January 28, 2003
Risedronate prevents hip fractures, but who should get therapy?Chad L Deal
Current Rheumatology Reports|April 18, 2007
Absolute fracture riskChad L Deal
Cleveland Clinic Journal of Medicine|February 5, 2013
Recent recommendations on steroid-induced osteoporosis: more targeted, but more complicatedChad L Deal
Women'S Health (London, England)|October 7, 2009
Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safetyChad L Deal, Michael W Draper
Arthritis and Rheumatism|October 3, 2006
Successes and failures in improving osteoporosis care after fragility fracture: results of a multiple-site clinical improvement projectJ Timothy Harrington, Chad L Deal
Arthritis Care & Research|July 19, 2012
Prevalence of oral glucocorticoid usage in the United States: a general population perspectiveRobert A Overman, Jun-Yen Yeh, Chad L Deal
Bone Reports|December 5, 2019
Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtendChad L Deal, Bruce H Mitlak, Yamei Wang, et al.
Arthritis Care & Research|April 11, 2014
United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosisRobert A Overman, Joshua C Toliver, Jun-Yen Yeh, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|February 22, 2015
DXA Utilization Between 2006 and 2012 in Commercially Insured Younger Postmenopausal WomenRobert A Overman, Joel F Farley, Jeffrey R Curtis, et al.
Arthritis and Rheumatism|March 1, 2007
The United States rheumatology workforce: supply and demand, 2005-2025Chad L Deal, Roderick Hooker, Timothy Harrington, et al.
Pageof 2